Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex Therapeutics

Related CLDX
Here's The Latest Biotech Breakout
This Biotech Stock Is Ready To Run

In a report published Friday, Jefferies & Company reiterated its Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and slightly raised its price target from $6.00 to $7.00.

Jefferies noted, “CLDX released an incremental pipeline update w/ focus on more mature data from CDX-011 EMERGE trial scheduled for presentation at San Antonio Breast mtg on 12/8. We expect EMERGE dataset along w/ FDA end of PhII mtg at year-end should help to guide CDX-011's late-stage development strategy. We continue to maintain a Buy based on the company's pipeline potential.”

Celldex Therapeutics closed on Thursday at $5.60.

Latest Ratings for CLDX

DateFirmActionFromTo
Sep 2014Cowen & CompanyInitiates Coverage onOutperform
Jul 2013Guggenheim SecuritiesInitiates Coverage onBuy
Jun 2013OppenheimerMaintainsOutperform

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CLDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters